Science

“We think that it's too early, and we think it's really, ah, damaging for the science, ah, to actually move into such an opaque regime, where you have A few companies basically doing the same thing, just not communicating about it spending billions of compute d…”

“And so there's so much of science that lives in like folklore and institutional knowledge, and that's kind of lost over time.”

“I go back to that sort of returns to intelligence piece where I think science is a problem that has some shape to it that really benefits from the LLM architecture. Like you just think about the corpus of scientific literature as like this vast pool of unstruc…”

“So it took us about two years for post acquisition to get it to the place where this was possible, but we just in July got marketing approval in Europe for Prima to start commercially selling it there.”

“The TAM will grow over time for this first version. It's on the scale of like hundreds of thousands of patients in the U S and Europe. So for the current version of Freeman is probably hundreds of thousands of patients. And then the next version, which is Goin…”

“Specifically this is diseases like macular degeneration, which our clinical trial was done and we're about to do studies in retinitis pigmentosa and Stargardt's and a couple of their diseases.”

“Second site, 10 years ago, they, so there's a company about a decade ago that had a retinal prosthesis that works differently than ours does. It did not get the type of performance that Prima does, but was Briefly approved. Cause then there's really nothing fo…”

“In the mid-twenty-tens, there's a gene therapy that works, that is only relevant in the first place for about five percent of patients in one narrow indication. And it really doesn't work that well. It gets .one lines of improvement. It kind of slows the rate …”

“The first sales will happen in the coming weeks.”

“We use that constructively at science like that. So we know that that is. That is true because we can get alignments between animal brain neural recordings and AI model internal representations.”

“What we ended up doing is we developed indigenously a state of the art gene therapy, which is probably going to humans next year.”